Sherene Loi

Sherene Loi is an internationally recognized leader in breast cancer immunology and has made seminal contributions to establishing tumor-infiltrating lymphocytes (TILs) as a prognostic and predictive biomarker in triple-negative and HER2-positive breast cancer. She led the international TIL Working Group that developed standardized assessment methods for TILs in breast cancer. Her translational research connects immune genomics with clinical outcomes and immunotherapy response. She has been involved in multiple landmark breast cancer immunotherapy trials and is one of the most influential young investigators in the field.